FLAG-Ida强化治疗可能改善年轻继发性急性髓系白血病患者的疾病控制:MRC AML15试验长期随访
MRC AML15试验在年轻继发性急性髓系白血病患者中比较FLAG-Ida与DA/ADE诱导方案。该亚组(n=115)中,完全缓解/完全缓解伴血液学不完全恢复率无差异(81% vs 79%),但FLAG-Ida的5年总生存率和无复发生存率更优[37% vs 27%,分层HR 0.45(0.33-0.90)P=0.02;41% vs 22%,分层HR 0.54(0.31-0.96)P=0.04]。
要点
- 年轻继发性AML患者中,FLAG-Ida与DA/ADE的完全缓解/完全缓解伴血液学不完全恢复率无差异(81% vs 79%)。
- FLAG-Ida组5年总生存率37% vs DA/ADE组27%,分层HR 0.45(0.33-0.90)P=0.02。
- FLAG-Ida组5年无复发生存率41% vs DA/ADE组22%,分层HR 0.54(0.31-0.96)P=0.04。
核心结论
- 年轻继发性AML患者可能从治疗强化中获益,且「3+7」可能不是该组患者试验中的最佳对照方案。
研究设计与样本
- MRC AML15试验将年轻患者随机分配至柔红霉素联合阿糖胞苷(DA)与DA联合依托泊苷(ADE)及ADE联合氟达拉滨、阿糖胞苷、伊达比星和粒细胞集落刺激因子(FLAG-Ida)诱导方案。
- 本次报告年龄<60岁继发性AML患者亚组(n=115)的长期随访结果。
主要发现
- 诱导缓解率无差异:完全缓解/完全缓解伴血液学不完全恢复率为81% vs 79%。
- 5年总生存率FLAG-Ida组37% vs DA/ADE组27%,分层HR 0.45(0.33-0.90)P=0.02。
- 5年无复发生存率FLAG-Ida组41% vs DA/ADE组22%,分层HR 0.54(0.31-0.96)P=0.04。
关键数值与推荐
- 年龄<60岁继发性AML患者亚组共115例。
- 完全缓解/完全缓解伴血液学不完全恢复率:FLAG-Ida组81% vs DA/ADE组79%。
- 5年总生存率:FLAG-Ida组37% vs DA/ADE组27%,分层HR 0.45(0.33-0.90)P=0.02。
- 5年无复发生存率:FLAG-Ida组41% vs DA/ADE组22%,分层HR 0.54(0.31-0.96)P=0.04。
临床怎么用
- 作者认为年轻继发性AML患者可能从治疗强化中获益,且「3+7」可能不是该组患者试验中的最佳对照方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Secondary acute myeloid leukaemia (AML) has a poor outcome following "3 + 7-like" chemotherapy. While CPX-351 has been approved for patients aged 60-75, the optimal treatment, or comparator, in younger patients is less clear. The MRC AML15 trial randomised younger patients between daunorubicin and ara-C (DA) and DA plus etoposide (ADE) and ADE and fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor (FLAG-Ida) induction. Overall results failed to show an overall survival benefit for FLAG-Ida despite a reduction in relapse, the outcome of patients <60 years with secondary AML compared to DA/ADE was not reported. In this group (n = 115) response to induction was not different [complete remission/complete remission with incomplete haematological response 81% vs. 79%), however, 5-year overall survival and relapse free survival was superior for FLAG-Ida [37% vs. 27%, stratified hazard ratio (HR) 0·45 (0·33-0·90) P = 0·02 and 41% vs. 22%; stratified HR 0·54 (0·31-0·96) P = 0·04] respectively, suggesting that younger patients with secondary AML may benefit from treatment intensification and that "3 + 7" may not be the optimal comparator in trials for this group of patients.
引用
- Russell N, Hills R, Kjeldsen L, et al. Treatment intensification with FLAG-Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long-term follow up of the MRC AML15 trial. Br J Haematol. 2021. PMID: 34904225. doi:10.1111/bjh.17974
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。